{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:55:46Z","timestamp":1791244546167,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.spen.2021.100878","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T21:12:17Z","timestamp":1612991537000},"page":"100878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Spinal Muscular Atrophy"],"prefix":"10.1016","volume":"37","author":[{"given":"Stefan","family":"Nicolau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan A.","family":"Waldrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spen.2021.100878_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: Clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0002","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.neuron.2005.12.001","article-title":"Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease","volume":"48","author":"Monani","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.spen.2021.100878_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11910-017-0798-y","article-title":"Treatment advances in spinal muscular atrophy","volume":"17","author":"Bharucha-Goebel","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.spen.2021.100878_bib0004","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2021.100878_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11940-019-0568-z","article-title":"Current treatment options in neurology\u2014SMA therapeutics","volume":"21","author":"Waldrop","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.spen.2021.100878_bib0006","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/B978-0-444-64076-5.00038-7","article-title":"Spinal muscular atrophy","volume":"148","author":"Arnold","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.spen.2021.100878_bib0007","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"key":"10.1016\/j.spen.2021.100878_bib0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.spen.2021.100878_bib0009","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100878_bib0010","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","article-title":"The changing natural history of spinal muscular atrophy type 1","volume":"69","author":"Oskoui","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100878_bib0011","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2021.100878_bib0012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","article-title":"A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients","volume":"146","author":"Zerres","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.spen.2021.100878_bib0013","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.spen.2021.100878_bib0014","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.ejhg.5200667","article-title":"Best practice guidelines for molecular analysis in spinal muscular atrophy","volume":"9","author":"Scheffer","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/GIM.0b013e318220d523","article-title":"Technical standards and guidelines for spinal muscular atrophy testing","volume":"13","author":"Prior","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.spen.2021.100878_bib0016","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1086\/498853","article-title":"Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2","volume":"78","author":"Cartegni","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ng854","article-title":"Disruption of an SF2\/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1","volume":"30","author":"Cartegni","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0019","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","article-title":"The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-\/-) mice and results in a mouse with spinal muscular atrophy","volume":"9","author":"Monani","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0020","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","article-title":"Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos","volume":"94","author":"Schrank","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2021.100878_bib0021","doi-asserted-by":"crossref","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.spen.2021.100878_bib0022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0023","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1542\/peds.110.2.e24","article-title":"Respiratory support in spinal muscular atrophy type I: A survey of physician practices and attitudes","volume":"110","author":"Hardart","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.spen.2021.100878_bib0024","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ppul.21617","article-title":"International survey of physician recommendation for tracheostomy for Spinal Muscular Atrophy Type I","volume":"47","author":"Benson","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.spen.2021.100878_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0026","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007742","article-title":"Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy","volume":"93","author":"Wijngaarde","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100878_bib0027","doi-asserted-by":"crossref","DOI":"10.1097\/BPO.0000000000001049","article-title":"Outcomes of primary posterior spinal fusion for scoliosis in spinal muscular atrophy: clinical, radiographic, and pulmonary outcomes and complications","volume":"37","author":"Holt","year":"2017","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.spen.2021.100878_bib0028","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00586-016-4828-2","article-title":"The effect of scoliosis surgery on pulmonary function in spinal muscular atrophy type II patients","volume":"26","author":"Chou","year":"2017","journal-title":"Eur Spine J"},{"key":"10.1016\/j.spen.2021.100878_bib0029","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.nmd.2012.04.008","article-title":"Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type I","volume":"22","author":"Poruk","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/joa.12083","article-title":"Spinal muscular atrophy: A motor neuron disorder or a multi-organ disease?","volume":"224","author":"Shababi","year":"2014","journal-title":"J Anat"},{"key":"10.1016\/j.spen.2021.100878_bib0031","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: Going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.spen.2021.100878_bib0032","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13023-017-0613-5","article-title":"Cardiac pathology in spinal muscular atrophy: A systematic review","volume":"12","author":"Wijngaarde","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.spen.2021.100878_bib0033","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3233\/JND-160177","article-title":"Type 0 spinal muscular atrophy: Further delineation of prenatal and postnatal features in 16 patients","volume":"3","author":"Grotto","year":"2016","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.spen.2021.100878_bib0034","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/jmg.2008.057950","article-title":"Congenital heart disease is a feature of severe infantile spinal muscular atrophy","volume":"45","author":"Rudnik-Schoneborn","year":"2008","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0035","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI131989","article-title":"Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models","volume":"130","author":"Kim","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.spen.2021.100878_bib0036","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0037","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: Current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.spen.2021.100878_bib0038","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","article-title":"A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse","volume":"21","author":"Porensky","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0039","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100878_bib0040","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2021.100878_bib0041","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2021.100878_bib0042","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0043","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2021.100878_bib0044","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.26633","article-title":"Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy","volume":"60","author":"Montes","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100878_bib0045","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100878_bib0046","first-page":"194","article-title":"Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.spen.2021.100878_bib0047","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nmd.2018.10.001","article-title":"The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy","volume":"29","author":"Kletzl","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0048","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.spen.2021.100878_bib0049","doi-asserted-by":"crossref","first-page":"11021","DOI":"10.1021\/acs.jmedchem.8b01291","article-title":"Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Cheung","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.spen.2021.100878_bib0050","article-title":"New and developing therapies in spinal muscular atrophy: From genotype to phenotype to treatment and where do we stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.spen.2021.100878_bib0051","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2021.100878_bib0052","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.spen.2021.100878_bib0053","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.spen.2021.100878_bib0054","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100878_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0056","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2015.07.006","article-title":"Adeno-associated virus serotypes for gene therapeutics","volume":"24","author":"Lisowski","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.spen.2021.100878_bib0057","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2021.100878_bib0058","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.spen.2021.100878_bib0059","doi-asserted-by":"crossref","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: Safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.spen.2021.100878_bib0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.spen.2021.100878_bib0061","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving forward after two deaths in a gene therapy trial of myotubular myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.spen.2021.100878_bib0062","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.gt.3303037","article-title":"Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice","volume":"15","author":"Petry","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.spen.2021.100878_bib0063","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: Preclinical to clinical planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.spen.2021.100878_bib0064","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.spen.2021.100878_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167087","article-title":"A comparative study of SMN protein and mRNA in blood and fibroblasts in patients with spinal muscular atrophy and healthy controls","volume":"11","author":"Wadman","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.spen.2021.100878_bib0066","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.spen.2021.100878_bib0067","series-title":"Presentation at the 2020 virtual congress of the World Muscle Society","article-title":"Long-term follow-up of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1 (SMA1)","author":"Mendell","year":"2020"},{"key":"10.1016\/j.spen.2021.100878_bib0068","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/humc.2017.010","article-title":"Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson's disease","volume":"28","author":"Sehara","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.spen.2021.100878_bib0069","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: Comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1","volume":"36","author":"Dabbous","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.spen.2021.100878_bib0070","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1212\/WNL.0000000000008207","article-title":"Combination therapy with nusinersen and AVXS-101 in SMA type 1","volume":"93","author":"Lee","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100878_bib0071","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100878_bib0072","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.spen.2021.100878_bib0073","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1073\/pnas.0604893104","article-title":"Lack of myostatin results in excessive muscle growth but impaired force generation","volume":"104","author":"Amthor","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2021.100878_bib0074","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/s41598-018-20524-9","article-title":"Blocking extracellular activation of myostatin as a strategy for treating muscle wasting","volume":"8","author":"Pirruccello-Straub","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.spen.2021.100878_bib0075","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","article-title":"Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy","volume":"28","author":"Long","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0076","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.2618","article-title":"Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases","volume":"18","author":"Russell","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.spen.2021.100878_bib0077","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.114.222224","article-title":"The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure","volume":"353","author":"Hwee","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.spen.2021.100878_bib0078","first-page":"1","article-title":"A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis","volume":"0","author":"Shefner","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.spen.2021.100878_bib0079","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mus.26017","article-title":"CK-2127107 amplifies skeletal muscle response to nerve activation in humans","volume":"57","author":"Andrews","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100878_bib0080","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1474-4422(14)70201-7","article-title":"Congenital myasthenic syndromes: Pathogenesis, diagnosis, and treatment","volume":"14","author":"Engel","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100878_bib0081","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.nmd.2018.07.013","article-title":"Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy?","volume":"28","author":"Pera","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0082","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmg.2010.080366","article-title":"Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: Relevance for clinical trial design","volume":"47","author":"Tiziano","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0083","first-page":"351","article-title":"Salbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cells","volume":"4","author":"Harahap","year":"2015","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.spen.2021.100878_bib0084","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","author":"Pane","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0085","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot trial of albuterol in spinal muscular atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100878_bib0086","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.nmd.2019.04.003","article-title":"Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II","volume":"29","author":"Frongia","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0087","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pediatrneurol.2017.04.013","article-title":"Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy","volume":"73","author":"Khirani","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2021.100878_bib0088","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmedgenet-2018-105482","article-title":"Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: Results of a phase IIb double-blind study of salbutamol","volume":"56","author":"Tiziano","year":"2019","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2021.100878_bib0089","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.spen.2021.100878_bib0090","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P1.6-057","article-title":"AVXS-101 gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): Study update (P1.6-057)","volume":"92","author":"Schultz","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100878_bib0091","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","article-title":"244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands","volume":"30","author":"Dangouloff","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100878_bib0092","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.spen.2021.100878_bib0093","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.spen.2021.100878_bib0094","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/aogs.13858","article-title":"Impact of a national genetic carrier-screening program for reproductive purposes","volume":"99","author":"Singer","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.spen.2021.100878_bib0095","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41436-020-0824-3","article-title":"Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy","volume":"22","author":"Kay","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.spen.2021.100878_bib0096","article-title":"Committee opinion no. 691: Carrier screening for genetic conditions","volume":"129","year":"2017","journal-title":"Obstet Gynecol"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909121000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909121000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:38:45Z","timestamp":1761028725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909121000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":96,"alternative-id":["S1071909121000061"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2021.100878","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spinal Muscular Atrophy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spen.2021.100878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100878"}}